Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 9/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.39 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KDM6B | O15054 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5030186 | 0.90 | KDM4C (0.45) | EGLN1KDM4CEGFRSRCFTO | |
| SCHEMBL523958 | 0.80 | EGLN1 (0.59) | EGLN1FTOBBOX1 | |
| SCHEMBL9893450 | 0.74 | EGLN1 (0.48) | EGLN1FTOBBOX1EGLN3VEGFA | |
| SCHEMBL9265977 | 0.73 | MEN1 (0.44) | ALDH1A1MAPTTP53RXFP1CYP1A2 | |
| SCHEMBL18496406 | 0.73 | EGLN1 (0.47) | EGLN1KDM4CFTOBBOX1 | |
| SCHEMBL5027693 | 0.72 | THRA (0.52) | EGLN1FTOBBOX1 | |
| SCHEMBL1514728 | 0.71 | ALDH1A1 (0.66) | EGLN1ALDH1A1MAPTTP53ATM | |
| SCHEMBL522660 | 0.70 | EGLN1 (0.59) | EGLN1FTOBBOX1EGLN3 | |
| SCHEMBL521900 | 0.70 | EGLN1 (0.66) | EGLN1FTOBBOX1KDM6B | |
| SCHEMBL5034433 | 0.69 | KDM4C (0.48) | EGLN1KDM4CEGFRFTOBBOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318703-B2 | Methods for improving kidney function | FIBROGEN, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120149712-A1 | Methods for improving kidney function | FIBROGEN, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149712-A1 | Methods for improving kidney function | ATP6V1B1, REN, GLS | EGLN1 1174/4885KDM4C 2448/4885ALDH1A1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.